Jared Kaltwasser

The findings support policies urging vaccination of individuals who have myasthenia gravis (MG).

Treatment options have improved care, but also increased the need for patient education.

About a quarter of joints examined had at least 1 joint bleed.

Investigators said data show social factors are intertwined with health outcomes.

A patient’s inability to count while holding their breath can be an indication of respiratory distress in myasthenia gravis.

Gene therapies could have a major impact, although the cost and complexities could inhibit their wide rollout, study authors said.

However, the patients also said they worried about insufficient care coordination between specialists and other care providers.

Investigators found patients with acute coronary syndrome were 3 times more likely to die in the hospital.

People with myasthenia gravis (MG) had a higher risk of hospitalization for COVID-19 compared to the general population and a control group of people with rheumatoid arthritis (RA).

Older people with psoriasis had a roughly 50% higher risk of being diagnosed with a malignancy, investigators found.

The projected cost reductions held both for patients switching from a different extended-half-life product and for patients switching from a standard-half-life product.

Ten-year mean costs associated with psoriasis-related health care visits were 10 times higher for patients with generalized pustular psoriasis (GPP).

Clinicians treating patients with polycythemia vera are too reliant upon phlebotomy, data suggest.

The data show how disease-modifying therapies are changing outcomes for children with spinal muscular atrophy (SMA), a rare neuromuscular disease.

A new case series highlights characteristics and challenges of this subgroup of patients with myasthenia gravis (MG).

Most patients with chronic thromboembolic pulmonary hypertension (CTEPH) said they can go about their daily activities without restriction, the authors found, because of gains in functional status and quality of life (QOL).

A review of cases involving Jehovah’s Witnesses found many modalities can be successfully deployed to treat thrombotic thrombocytopenic purpura (TTP).

Vaccines were safe in transplant recipients, but their efficacy was affected by immunosuppressive therapies.

More information is needed to better understand variations in how the drug affects individual patients.

The cost savings for health plans would increase if the therapy were used after the first recurrence of Clostridioides difficile infection (CDI).

A patient with myasthenia gravis (MG) quickly deteriorated after he woke up from an endovascular procedure.

The findings suggest recombinant ADAMTS-13 may be a useful adjunct therapy to plasma exchange among patients who have thrombotic thrombocytopenic purpura (iTTP).

The study was designed and conducted by undergraduate researchers.

The patient’s thrombotic thrombocytopenic purpura (TTP)–like symptoms were caused by deficiencies of vitamins B1 and B12.

The patient sought care for a mass in her right buttock, but had no tonsillar symptoms.

The impaired reactivity may play a role in organ injury, the authors suggested, among patients who have immune-mediated thrombotic thrombocytopenic purpura (iTTP).

The new research could help identify ways to preserve neuromuscular junctions.

Patients with myelofibrosis (MF) with single-hit mutations had similar outcomes to patients with wild-type TP53.

Judicious use of caplacizumab (Cablivi) can reduce the risk of severe bleeding and help manage costs associated with the therapy in patients living with thrombotic thrombocytopenic purpura (TTP).

Female patients were most likely to experience onset of triple-negative myasthenia gravis (MG) between ages 0 to 9 years.